LAPIX Therapeutics Reports Positive Bioequivalence for Oral Capsule and New Safety Milestones in the LPX-TI641 Program

• The new oral capsule advances into Phase Ib studies as GLP data establish a new NOAEL, expanding safety margins for LPX-TI641 development.

The release as fetched from its publisher. lapix.com ↗